Lilly to boost diabetes sales force

Share this article:
Eli Lilly said it expects to increase its diabetes sales force by 40% in 2007. The move comes as Lilly plans launch five new insulin pen delivery products and bolster efforts behind its recently launched diabetes treatment Byetta, Lilly president John Lechleiter told investors last Thursday. Byetta’s new-prescription volume increased 30% over the last month, Lilly said. The drug also recently won approval to be marketed in Europe.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.